|
US3201389A
(en)
|
1962-09-24 |
1965-08-17 |
Kyowa Hakko Kogyo Kk |
Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides
|
|
US3451997A
(en)
|
1965-11-30 |
1969-06-24 |
Kyowa Hakko Kogyo Kk |
Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
US4411995A
(en)
|
1981-09-28 |
1983-10-25 |
Massachusetts Institute Of Technology |
Synthesis of nicotinamide cofactors
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
CN100408100C
(zh)
|
1997-07-29 |
2008-08-06 |
阿尔康实验室公司 |
含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
|
|
JP2002501892A
(ja)
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な（−）−ビュープロピオンの薬学的使用
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
RS51031B
(sr)
|
2001-04-30 |
2010-10-31 |
Trommsdorff Gmbh & Co.Kg.Arzneimittel |
Farmaceutski aktivni estri uridina
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
US20040224039A1
(en)
|
2003-02-12 |
2004-11-11 |
Donald Brucker |
Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
|
|
US6887855B2
(en)
*
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
US8512717B2
(en)
|
2003-08-07 |
2013-08-20 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes and methods for making and using same
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
AU2004324323A1
(en)
|
2003-10-31 |
2006-06-15 |
Robarts Research Institute |
Methods and formulations for protecting cells, and for treating diseases and conditions by optimising the intracellular concentration of NAD
|
|
ES2663226T3
(es)
|
2004-06-04 |
2018-04-11 |
Washington University |
Procedimientos y composiciones para tratar neuropatías
|
|
WO2006094235A1
(en)
|
2005-03-03 |
2006-09-08 |
Sirtris Pharmaceuticals, Inc. |
Fused heterocyclic compounds and their use as sirtuin modulators
|
|
US20070149466A1
(en)
|
2005-07-07 |
2007-06-28 |
Michael Milburn |
Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
|
|
US7855289B2
(en)
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
JP5063878B2
(ja)
|
2005-08-30 |
2012-10-31 |
扶桑薬品工業株式会社 |
硫化水素塩を含有する消化器系疾患の予防／治療用組成物
|
|
US20080020413A1
(en)
*
|
2006-03-29 |
2008-01-24 |
Columbia University |
Crystalline visfatin and methods therefor
|
|
CA2646674A1
(en)
|
2006-04-20 |
2007-11-01 |
Fred Hutchinson Cancer Research Center |
Use of chalcogenides for treating shock and other adverse conditions
|
|
US20080318892A1
(en)
|
2006-04-28 |
2008-12-25 |
John Geoffrey Pickering |
Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
|
|
WO2007136744A1
(en)
*
|
2006-05-19 |
2007-11-29 |
The Johns Hopkins University |
Crystal structure of a substrate complex of nampt/pbef/visfatin
|
|
EP2124985A4
(en)
*
|
2007-01-26 |
2011-06-08 |
Univ Washington |
METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
|
|
CN101497638B
(zh)
|
2008-01-30 |
2012-09-26 |
中国科学院大连化学物理研究所 |
一种nad+类似物及其合成和应用
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
CN101601679B
(zh)
|
2009-03-17 |
2011-08-10 |
中国人民解放军第二军医大学 |
一种烟酰胺单核苷酸的应用
|
|
WO2010135520A1
(en)
|
2009-05-20 |
2010-11-25 |
Chimerix, Inc. |
Compounds, compositions and methods for treating viral infection
|
|
KR20110061909A
(ko)
*
|
2009-12-02 |
2011-06-10 |
삼성전자주식회사 |
도펀트로 도핑된 그라펜 및 이를 이용한 소자
|
|
EP2993236A1
(en)
|
2010-04-15 |
2016-03-09 |
Glaxosmithkline LLC |
Sirtuin activators and activation assays
|
|
US8481711B2
(en)
|
2010-07-06 |
2013-07-09 |
Hidenori Kamanishi |
Neurite outgrowth agent
|
|
RU2016116533A
(ru)
|
2010-09-03 |
2018-11-30 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
CN103384668B
(zh)
|
2010-09-03 |
2017-05-31 |
福马Tm有限责任公司 |
用于抑制nampt的化合物和组合物
|
|
CA2810049A1
(en)
|
2010-09-03 |
2012-03-08 |
Forma Tm, Llc |
Guanidine compounds and compositions for the inhibition of nampt
|
|
WO2012094343A1
(en)
|
2011-01-05 |
2012-07-12 |
Trilink Biotechnologies |
Chemically substituted thermosensitive probes and cofactors for hot start ligation
|
|
WO2012114204A2
(en)
|
2011-02-15 |
2012-08-30 |
Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto |
Methods of treating mitochondrial dysfunction
|
|
US20120107888A1
(en)
|
2011-02-17 |
2012-05-03 |
Qteros, Inc. |
Modulation of fermentation products through vitamin supplementation
|
|
RU2616612C2
(ru)
|
2011-05-04 |
2017-04-18 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
US20120328526A1
(en)
|
2011-06-27 |
2012-12-27 |
University Of Maryland, Baltimore |
Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
|
|
US20140221319A1
(en)
|
2011-06-29 |
2014-08-07 |
Mayo Foundation For Medical Education And Research |
Small Molecule CD38 Inhibitors and Methods of Using Same
|
|
US9458172B2
(en)
|
2012-03-02 |
2016-10-04 |
Kenneth W Bair |
Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
|
|
ES2620668T3
(es)
|
2012-03-02 |
2017-06-29 |
Genentech, Inc. |
Derivados de amidas y sulfonamidas amido espirocíclicas
|
|
WO2013130943A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
|
|
WO2013127268A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech,Inc. |
Amido-benzyl sulfone and sulfonamide derivatives
|
|
JP2015508784A
(ja)
|
2012-03-02 |
2015-03-23 |
ジェネンテック， インコーポレイテッド |
アミド−ベンジルスルホン及びスルホキシド誘導体
|
|
JP6289460B2
(ja)
|
2012-07-16 |
2018-03-07 |
コーネル ユニヴァーシティー |
難聴を治療するためのニコチンアミドリボシド
|
|
WO2014059034A2
(en)
*
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
|
CN102876759A
(zh)
*
|
2012-10-29 |
2013-01-16 |
尚科生物医药（上海）有限公司 |
尼克酰胺腺嘌呤二核苷酸的制备方法
|
|
WO2014074715A1
(en)
|
2012-11-07 |
2014-05-15 |
Genentech, Inc. |
Cyclopropyl amide derivatives
|
|
WO2014111906A1
(en)
|
2013-01-21 |
2014-07-24 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Bioluminescence imaging of small biomolecules
|
|
PL2968306T3
(pl)
|
2013-03-15 |
2024-01-29 |
Washington University |
Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
|
|
US20140271355A1
(en)
|
2013-03-15 |
2014-09-18 |
Sabre Intellectual Property Holdings Llc |
Apparatus and process for focused gas phase application of biocide
|
|
GB201313465D0
(en)
|
2013-07-29 |
2013-09-11 |
Queens University Of The Belfast |
Methods of preparing nicotinamide riboside and derivatives thereof
|
|
US20160287621A1
(en)
|
2013-11-06 |
2016-10-06 |
President And Fellows Of Harvard College |
Biological production of nad precursors and analogs
|
|
US10398701B2
(en)
|
2013-11-12 |
2019-09-03 |
Ortho-Nutra, Llc |
Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
|
|
CN105992521A
(zh)
|
2013-11-12 |
2016-10-05 |
奥索努特拉有限责任公司 |
基于特咖宁的补充剂及其使用方法
|
|
EP3068364B1
(en)
|
2013-11-14 |
2021-11-03 |
Metro Biotech NSW Pty Ltd |
Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
|
|
CN104367587B
(zh)
|
2013-12-06 |
2018-06-29 |
中国人民解放军第二军医大学 |
烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用
|
|
US20150258052A1
(en)
|
2014-03-13 |
2015-09-17 |
Salk Institute For Biological Studies |
Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
|
|
JP2017511304A
(ja)
|
2014-03-13 |
2017-04-20 |
ソーク インスティチュート フォー バイオロジカル スタディーズ |
フェキサラミン類似体ならびに作製方法および使用方法
|
|
US10301268B2
(en)
|
2014-03-13 |
2019-05-28 |
The Salk Institute For Biological Studies |
Analogs of fexaramine and methods of making and using
|
|
MX2016015997A
(es)
|
2014-06-02 |
2017-04-05 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
|
|
MX2016015907A
(es)
|
2014-06-03 |
2018-08-01 |
Sulfagenix Inc |
Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas.
|
|
US10485814B2
(en)
|
2014-06-06 |
2019-11-26 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
|
|
CA2956163C
(en)
|
2014-07-24 |
2023-01-10 |
W.R. Grace & Co.-Conn. |
Crystalline form of nicotinamide riboside
|
|
WO2016086088A2
(en)
|
2014-11-25 |
2016-06-02 |
Northwestern University |
Wound healing through sirt1 overexpression
|
|
US20170326100A1
(en)
|
2014-12-09 |
2017-11-16 |
Amorepacific Corporation |
Composition for activating longevity gene
|
|
CN107428791B
(zh)
|
2015-03-09 |
2024-05-28 |
格雷斯公司 |
烟酰胺核苷的结晶形式
|
|
CN104817604B
(zh)
|
2015-03-16 |
2017-08-04 |
邦泰生物工程(深圳)有限公司 |
一种β‑烟酰胺单核苷酸的纯化方法
|
|
EP3271456A1
(en)
|
2015-03-18 |
2018-01-24 |
The Regents of the University of California |
Methods of preventing and reversing stem cell aging
|
|
CA2987986A1
(en)
|
2015-06-04 |
2016-12-08 |
Chromadex, Inc. |
Selective solvent free phosphorylation
|
|
WO2016210232A1
(en)
|
2015-06-25 |
2016-12-29 |
N.V. Perricone Llc |
Niacinamide mononucleotide formulations for skin aging
|
|
US9855289B2
(en)
|
2015-08-05 |
2018-01-02 |
Metro International Biotech, Llc |
Nicotinamide mononucleotide derivatives and their uses
|
|
TW201713774A
(zh)
|
2015-08-06 |
2017-04-16 |
Kohjin Life Sciences Co Ltd |
含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法
|
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
|
CA3001483A1
(en)
|
2015-10-07 |
2017-04-13 |
Joel HUIZENGA |
Resetting biological pathways for defending against and repairing deterioration from human aging
|
|
WO2017079195A1
(en)
|
2015-11-02 |
2017-05-11 |
Mitobridge, Inc. |
Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
|
|
WO2017110317A1
(ja)
|
2015-12-21 |
2017-06-29 |
昭和電工株式会社 |
ニコチンアミドモノヌクレオチド誘導体、その塩、その製造方法、皮膚外用剤、化粧料、食品添加剤
|
|
EP3187180A1
(en)
|
2015-12-28 |
2017-07-05 |
Ludwig-Maximilians-Universität München |
Adenosylhomocysteinase binding substances for medical use
|
|
WO2017145151A1
(en)
|
2016-02-23 |
2017-08-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Process for preparation of nicotinamide riboside (nr) and cosmetic composition comprising (nr and a phosphate-binding agent
|
|
CA3017254C
(en)
|
2016-03-16 |
2023-08-22 |
ChromaDex Inc. |
B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
|
|
US10183036B2
(en)
|
2016-04-20 |
2019-01-22 |
ChromaDex Inc. |
Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors
|
|
WO2017218580A1
(en)
|
2016-06-14 |
2017-12-21 |
Rejuvenation Therapeutics Corporation |
Synthetic methods for the preparation of nicotinamide riboside and related compounds
|
|
CN107922952B
(zh)
|
2016-07-30 |
2021-04-27 |
邦泰生物工程(深圳)有限公司 |
一种制备烟酰胺单核苷酸的方法
|
|
CN107889504B
(zh)
|
2016-07-30 |
2021-07-27 |
邦泰生物工程(深圳)有限公司 |
一种制备烟酰胺单核苷酸的方法
|
|
CN108026132B
(zh)
|
2016-07-30 |
2021-08-13 |
邦泰生物工程(深圳)有限公司 |
一种烟酰胺单核苷酸的纯化方法
|
|
WO2017185549A1
(zh)
|
2016-07-30 |
2017-11-02 |
邦泰生物工程(深圳)有限公司 |
一种制备烟酰胺单核苷酸的方法2
|
|
WO2018023210A1
(zh)
|
2016-07-30 |
2018-02-08 |
邦泰生物工程(深圳)有限公司 |
一种制备烟酰胺单核苷酸的方法
|
|
WO2018023209A1
(zh)
|
2016-07-30 |
2018-02-08 |
邦泰生物工程(深圳)有限公司 |
一种制备烟酰胺单核苷酸的方法
|
|
WO2018047715A1
(ja)
*
|
2016-09-06 |
2018-03-15 |
協和発酵バイオ株式会社 |
β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
|
|
CN109691011B
(zh)
|
2016-09-09 |
2022-06-14 |
日本电气株式会社 |
发送装置、接收装置、量子密钥分发方法和介质
|
|
US20200009170A1
(en)
|
2016-09-13 |
2020-01-09 |
Megumi Tanaka |
Sleep display agent property and method for improving sleep disorders
|
|
ES2955713T3
(es)
|
2016-09-13 |
2023-12-05 |
Megumi Tanaka |
Agente de mejora de la función visual, y método para mejorar la función visual
|
|
CN120383644A
(zh)
|
2016-11-11 |
2025-07-29 |
英国贝尔法斯特女王大学 |
烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
|
|
CN110325190A
(zh)
|
2016-12-21 |
2019-10-11 |
新南创新私人有限公司 |
增加血管密度的方法
|
|
CN106755209B
(zh)
|
2016-12-29 |
2021-07-23 |
苏州汉酶生物技术有限公司 |
一种酶法制备β-烟酰胺单核苷酸的方法
|
|
EP3568488A4
(en)
|
2017-01-13 |
2020-09-23 |
The Regents of The University of Colorado, A Body Corporate |
METHODS OF TREATMENT OF HYPERTENSION AND ARTERIAL RIGIDITY
|
|
JP6974360B2
(ja)
|
2017-01-31 |
2021-12-01 |
オリエンタル酵母工業株式会社 |
多分化能性幹細胞増殖促進剤
|
|
JP6920071B2
(ja)
|
2017-02-16 |
2021-08-18 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
アディポネクチン分泌向上剤
|
|
JP7182289B2
(ja)
|
2017-04-05 |
2022-12-02 |
コーネル ユニヴァーシティー |
β－ニコチネートエステルヌクレオチドおよびその調製プロセス
|
|
WO2019023748A1
(en)
|
2017-07-31 |
2019-02-07 |
Newsouth Innovations Pty Limited |
METHODS FOR INCREASING FERTILITY
|
|
AU2019214858B2
(en)
|
2018-01-30 |
2023-02-02 |
Metro International Biotech, Llc |
Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
|
|
US20210388018A1
(en)
|
2018-10-01 |
2021-12-16 |
Cornell University |
Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof
|
|
MX2021006788A
(es)
|
2018-12-10 |
2022-04-01 |
Chromadex Inc |
Formas cristalinas de los ribósidos de nicotinoílo y derivados de estos, y métodos de preparación de estas.
|
|
JP2022523864A
(ja)
|
2019-03-22 |
2022-04-26 |
メトロ インターナショナル バイオテック，エルエルシー |
ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法
|
|
US11939348B2
(en)
|
2019-03-22 |
2024-03-26 |
Metro International Biotech, Llc |
Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
|
|
US10618927B1
(en)
|
2019-03-22 |
2020-04-14 |
Metro International Biotech, Llc |
Compositions and methods for modulation of nicotinamide adenine dinucleotide
|
|
WO2021234009A1
(fr)
|
2020-05-20 |
2021-11-25 |
Nuvamid Sa |
Compositions cosmetiques anti-age comprenant du nmn
|
|
KR20240020716A
(ko)
|
2021-05-27 |
2024-02-15 |
메트로 인터내셔널 바이오테크 엘엘씨 |
니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
|